(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 May 2022 (05.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/091056 A1

(51) International Patent Classification:
C07D 401/12 (2006.01) *A61K 31/4427* (2006.01)
C07D 405/12 (2006.01) *A61P 17/02* (2006.01)
C07D 413/12 (2006.01) *A61P 17/06* (2006.01)
C07D 417/12 (2006.01) *A61P 37/00* (2006.01)
C07D 487/04 (2006.01)

(21) International Application Number:
PCT/IB2021/060092

(22) International Filing Date:
01 November 2021 (01.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20205121.5 02 November 2020 (02.11.2020) EP

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors: **TROXLER, Thomas Josef**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **ORAIN, David**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **FURET, Pascal**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **WEIGAND, Klaus**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **SCHLAPBACH, Achim**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH).

(74) Agent: **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: INTERLEUKIN-17 INHIBITORS

(57) Abstract: The present invention relates to novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds that are Interleukin-17 (IL-17) inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by IL-17.

WO 2022/091056 A1